Liminal BioSciences Inc. announced that the FDA has approved Ryplazim (plasminogen, human-tvmh) for the treatment of patients with plasminogen deficiency type 1 (hypoplasminogenia) through its subsidiary, Prometic Biotherapeutics… read more.
Scynexis Inc.,. announced that the FDA has approved Brexafemme(ibrexafungerp tablets), for oral use in patients with vulvovaginal candidiasis (VVC), also known as vaginal yeast infection. Brexafemme which represents… read more.
Four months of multi-drug therapy that included rifapentine and moxifloxacin treated active tuberculosis (TB) as effectively as the standard six-month regimen in a multinational study, cutting treatment time… read more.
Surprisingly, despite widespread use, no one understood exactly how most mosquito repellents keep the insects away. Now researchers are starting to uncover the first pieces of the puzzle…. read more.
The four-year project took samples from patients hospitalised with influenza at up to five time points during their hospital stay, and 30 days after discharge. They analysed the… read more.
Researchers from the University of Oxford and their partners have today reported findings from a Phase IIb trial of a candidate malaria vaccine, R21/Matrix-M, which demonstrated high-level efficacy… read more.
The use of ivermectin for prophylaxis and treatment of covid-19 in Zimbabwe has resulted in a 10-fold reduction in mortality. IMI interviewed Dr Jackie Stone, a family medicine physician in based in Harare, Zimbabwe to find out more.
Interview and article by Christine Clark In the first ten years of the UK national HPV vaccination programme more than ten million doses of HPV vaccine were given… read more.
Gilead Sciences, Inc. announced new, long-term data from open-label extensions (OLE) of two Phase III studies (Study 1489 and Study 1490) of Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir… read more.
Interview and article by Christine Clark Cervical cancer accounts for about 850 cancer deaths in the UK every year – more than two every day – and yet… read more.
ViiV Healthcare, owned by GlaxoSmithKline, announced the European Marketing Authorisation of Rukobia (fostemsavir) 600mg extended-release tablets..
Article written by Christine Clark. During the past week Slovakia became the first European country to give formal approval for the use of ivermectin for both prophylaxis and… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
